Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim

Equities research analysts at Guggenheim assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $96.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 72.04% from the stock’s current price.

KROS has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Oppenheimer began coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Bank of America reduced their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $90.63.

Keros Therapeutics Price Performance

KROS opened at $55.80 on Monday. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The stock has a market cap of $2.01 billion, a P/E ratio of -10.83 and a beta of 1.22. The stock’s 50 day simple moving average is $49.53 and its 200 day simple moving average is $52.97.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the business earned ($1.27) earnings per share. Research analysts expect that Keros Therapeutics will post -4.78 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 1.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after purchasing an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Keros Therapeutics by 8.8% in the 1st quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock worth $468,000 after purchasing an additional 574 shares during the period. Arizona State Retirement System lifted its stake in shares of Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares in the last quarter. Finally, American International Group Inc. grew its holdings in shares of Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after purchasing an additional 1,465 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.